Polycyclo Ring System Having The Lactone Ring As One Of The Cyclos Patents (Class 549/275)
  • Patent number: 10314815
    Abstract: The present invention provides a crystalline Form A of Compound 1, also referred to as Granaticin B, and pharmaceutically compositions thereof. The present invention also provides methods of treating a microbial infection, or a disease, disorder, or condition associated with abnormal cellular proliferation, using crystalline Form A of Compound 1 or pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 11, 2019
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventor: Tero Kunnari
  • Publication number: 20150141252
    Abstract: A method of screening for a plant defense activator, which enhances an immune response of a plant, from at least one candidate substance includes: contacting a plant cell in which a jasmonic acid-dependent defense pathway and a salicylic acid-dependent defense pathway of a plant defense system are capable of working independently from each other, with a candidate substance; contacting the plant cell with a trigger material that induces an immune response; and assaying the plant cell after contacting with the trigger material based on an index representing an immune response, to select a target substance that enhances an immune response of the plant. A method of enhancing an immune response of a plant includes use of a specific compound, and a plant immune response enhancer includes the specific compound.
    Type: Application
    Filed: August 10, 2011
    Publication date: May 21, 2015
    Applicant: Tokyo University of Science Foundation
    Inventors: Kazuyuki Kuchitsu, Takamitsu Kurusu
  • Publication number: 20150045358
    Abstract: A pharmaceutical composition for treating disorders associated with insulin resistance is disclosed, and the composition comprises at least one inhibitor which is an effective agent to suppress endothelin-1-stimulated resistin gene expression through decreasing the endothelin-1-stimulated phosphorylation of proteins downstream of endothelin type A receptor, wherein the downstream signaling molecules comprise ERK1/2, JNKs, AKT, and STAT3 proteins, and wherein the inhibitor is selected from at least one antagonist of the endothelin type A receptor or downstream signaling proteins.
    Type: Application
    Filed: May 21, 2013
    Publication date: February 12, 2015
    Inventors: Yung-hsi KAO, Ya-chu Tang, Hsin-huei Chang, Hui-chen Ku
  • Patent number: 8952003
    Abstract: The present invention provides a sterol derivative or a pharmaceutically acceptable salt thereof having an activity to promote proliferation of neural stem cells. Namely, the present invention provides a sterol derivative represented by the general formula (I) (wherein Y represents optionally substituted lower alkyl or the like; Xa and Xb are the same or different, and represent a bond or the like; R1, R2, R3, R4, R7 and R8 are the same or different, and represent a hydrogen atom or the like; R5 and R6 are the same or different, and represent a hydrogen atom or the like; R9 represents a hydrogen atom or the like; R10 and R11 together represent a bond or the like; and R12 represents a hydrogen atom or the like) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: February 10, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Kenji Uchida, Tsutomu Agatsuma, Kazuhiro Hibino, Setsuya Sasho, Kyoichiro Iida, Hideyuki Onodera
  • Publication number: 20150011616
    Abstract: The present invention relates to novel chemical compounds, to methods for synthesis of such compounds, and to the use of these novel compounds in the synthesis of other chemical compounds that, inter alia, may be used in the treatment of sexual dysfunction, and for eliciting enhancing effects on sexual behavior. The invention also relates to remarkable biological properties of the novel compounds in their capacity of inducing aggressive behavior.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 8, 2015
    Inventors: Jarl Wikberg, Aigars Jirgensons, Edvards Liepinsh
  • Patent number: 8796476
    Abstract: Pest controlling compositions exhibiting enhanced pesticidal activity levels and methods for preparing the same are disclosed. In one embodiment, a method includes providing a liquid composition that includes at least one pesticide and at least one co-ingredient that enhances pesticidal activity of the composition compared to a composition dissimilar only in not having the at least one co-ingredient. The at least one co-ingredient may include at least one metal oxide, a combination of at least one transition metal salt and at least one proteinaceous material or a combination of at least one proteinaceous material and at least one polymeric material. The method further includes spray drying the liquid composition to provide a solid composition. In one aspect of this embodiment, the solid composition provided by the spray drying exhibits enhanced pesticidal activity compared to the liquid composition.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: August 5, 2014
    Assignee: Dow AgroSciences, LLC
    Inventors: Stephen L. Wilson, Lei Liu, James D. Thomas, Raymond E. Boucher, Jr., James E. Dripps, Margaret S. Kempe, Martin C. Logan, Douglas J. Linscott, John M. Atkinson
  • Patent number: 8697390
    Abstract: The present invention provides simple, rapid methods and procedures for analyzing cells, hereunder quantitative and qualitative assessment of cells. The present invention relates to the use of N-(9-acridinyl)maleimide (NAM) or to the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI), particularly detectable upon its reaction with species (e.g., sulphur-containing species) present in higher concentrations in intact (e.g., living) cells than in non-intact (e.g., dead) cells. The present invention also relates to the use of NAM or to the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI), particularly detectable upon its reaction with species present in intact and/or non-intact cells. Moreover, the present invention relates to the use of measuring techniques and/or instruments coupled with the use of NAM or with the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI).
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: April 15, 2014
    Assignee: ChemoMetec A/S
    Inventors: Mette Elena Skindersø, Helle Frobøse Sørensen, Søren Kjaerulff
  • Patent number: 8609870
    Abstract: Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C5 or C6 heteroaryl or heterocycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods and compounds for the treatment of disorders including neurologic, neuropsychiatric, and metabolic disorders are provided. For example, a method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of the described compounds.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: December 17, 2013
    Assignee: Emory University
    Inventor: Keqiang Ye
  • Patent number: 8604220
    Abstract: The subject of the invention is a novel molecule, Simalikalactone E, which can be extracted from the plant Quassia amara, and also the use thereof as a medicament, in particular in the prevention and treatment of malaria.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: December 10, 2013
    Assignee: Institut de Recherche Pour le Development
    Inventors: Valérie Jullian, Alexis Valentin, Eric Deharo, Geneviève Bourdy, Franciane Ho-A-Kwie, Nadia Cachet
  • Patent number: 8568794
    Abstract: Pharmaceutical or dermo-cosmetic compositions for topical and intravaginal application for treatment of human and veterinary affections caused by anaerobic organisms or parasites are provided comprising quassinoids or plant extracts containing these phytochemicals, in effective amounts. Such compositions can be administered topically or intravaginally to patients in need thereof in various pharmaceutical dosage forms.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: October 29, 2013
    Assignee: Life Science Investments, Ltd.
    Inventors: Christian Diehl, Silvia Chami De Diehl
  • Publication number: 20130046082
    Abstract: The present invention provides a composition including a polar organic extract of Eurycoma longifolia and a fraction derived from the polar organic extract, said composition comprising of quassinoids, coumarins, their glycosides, analogues and derivatives, which exhibits bioactivity of increasing spermatozoa production and spermatozoa quality in terms of morphology and motility, as well as increasing testosterone synthesis and release from cells of males. The extraction method of E. longifolia plant to produce the polar organic extract, and the subsequent purification to produce the fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives, and uses for manufacturing a preparation for infertility treatment are also provided. The fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives is formulated for medical applications via several routes of administration.
    Type: Application
    Filed: June 12, 2012
    Publication date: February 21, 2013
    Applicant: Universiti Sains Malaysia
    Inventors: Kit Lam CHAN, Bin Seng Low, David Sue San Ho
  • Publication number: 20120309819
    Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.
    Type: Application
    Filed: June 5, 2012
    Publication date: December 6, 2012
    Inventors: James D. McChesney, John T. Henri, Sylesh Kumar Venkataraman, Mahesh Kumar Gundluru
  • Publication number: 20120238566
    Abstract: Use of cell autophagy (type II cell apoptosis) inhibitors for preventing and/or treating avian influenza, injury of lungs caused by avian influenza virus or nanometer materials. The cell autophagy (type II cell apoptosis) inhibitors are selected from 3-methyladenine, SB203580, LY294002, and or wortmannin. The injury of lungs includes acute respiratory distress syndrome. The avian influenza virus is H5N1, H5N2 or H9N2 avian influenza virus. The nanometer materials include PAMAM G3, G4, G5, G5.5, G6, G7, or G8.
    Type: Application
    Filed: April 27, 2010
    Publication date: September 20, 2012
    Inventors: Chengyu Jiang, Shuan Rao, Haolin Liu, Feng Guo, Hongliang Wang, Yang Sun, Chenggang Li
  • Patent number: 8258318
    Abstract: There is provided a one-step process for producing a dihydroxy-substituted coumarin dimer compound by a photodimerization reaction of a hydroxy-substituted coumarin compound. The process comprises subjecting a hydroxy-substituted coumarin compound to a photodimerization reaction in a solvent selected from aliphatic ketones having 3 to 10 carbon atoms, aliphatic carboxylic acid esters having 2 to 10 carbon atoms, aliphatic alcohols having 1 to 10 carbon atoms, aliphatic nitriles having 2 to 10 carbon atoms, ethers having 4 to 10 carbon atoms, amides having 3 to 10 carbon atoms, and a mixture thereof to obtain a dihydroxy-substituted coumarin dimer compound.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: September 4, 2012
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Hideo Suzuki, Takayuki Tamura
  • Publication number: 20120172348
    Abstract: The present invention provides a sterol derivative or a pharmaceutically acceptable salt thereof having an activity to promote proliferation of neural stem cells. Namely, the present invention provides a sterol derivative represented by the general formula (I) (wherein Y represents optionally substituted lower alkyl or the like; Xa and Xb are the same or different, and represent a bond or the like; R1, R2, R3, R4, R7 and R8 are the same or different, and represent a hydrogen atom or the like; R5 and R6 are the same or different, and represent a hydrogen atom or the like; R9 represents a hydrogen atom or the like; R10 and R11 together represent a bond or the like; and R12 represents a hydrogen atom or the like) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 22, 2010
    Publication date: July 5, 2012
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenji Uchida, Tsutomu Agatsuma, Kazuhiro Hibino, Setsuya Sasho, Kyoichiro Iida, Hideyuki Onodera
  • Patent number: 8203009
    Abstract: Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C5 or C6 heteroaryl or hetero-cycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods and compounds for the treatment of disorders including neurologic, neuropsychiatric, and metabolic disorders are provided. For example, a method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of the described compounds.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: June 19, 2012
    Assignee: Emory University
    Inventor: Keqiang Ye
  • Publication number: 20120149767
    Abstract: The invention relates to a device (1) for connecting/disconnecting a submersible connector (100) provided with a male portion (101) and a female portion (102), to a related connection/disconnection method, as well as to the various potential uses of said device. The device includes means (11, 12) for moving at least one of said male or female portions of the connector (100) between a connection position and a disconnection position and vice versa, and is characterized in that it further includes a system (16) for injecting a fluid (20) around the male (101) and female (102) portions of the connector (100) when the latter passes from the connection position thereof to the disconnection position thereof and vice versa, in order to insulate the same from the water surrounding the connector (100), the injection system (16) being located outside the connector (100).
    Type: Application
    Filed: June 17, 2010
    Publication date: June 14, 2012
    Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
    Inventors: Valérie Jullian, Alexis Valentin, Eric Deharo, Geneviève Bourdy, Franciane Ho-A-Kwie, Nadia Cachet
  • Publication number: 20120011771
    Abstract: Disclosed is a novel compound contained in blue rose. This novel compound, which is contained in blue rose, has a chemical structure represented by general formula (I): [wherein R1 is a group as set forth in claim 1; and R2 represents —OH, or R1 and R2 together form —O—]. Also disclosed are a rose plant containing the aforesaid compound, and a part of the same.
    Type: Application
    Filed: March 25, 2010
    Publication date: January 19, 2012
    Applicant: SUNTORY HOLDINGS LIMITED
    Inventors: Yuko Fukui, Yoshikazu Tanaka
  • Publication number: 20110274656
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of Platycodon grandiflorum and/or saponin components in Platycodon grandiflorum useful as an antiviral agent. The composition of the present invention has no harm to human and inhibits the proliferation of Hepatitis C virus, so that it can be effectively used as a preventive or therapeutic agent for Hepatitis C.
    Type: Application
    Filed: January 21, 2010
    Publication date: November 10, 2011
    Applicant: B&C Biopharm Co., Ltd.
    Inventors: Jong Woo Kim, Sang Wook Lee, Sang Jin Park, Jung Cheul Shin, Jae Won Yang, Jong Hwan Lim
  • Publication number: 20110263693
    Abstract: Based on the discovery that celastrol and gedunin are Hsp90 inhibitors, the present invention provides novel inhibitors of Hsp90. and pharmaceutically acceptable salts, derivatives, and compositions thereof. The invention provides two classes of compounds. One class includes celastrol and its derivatives. The other class includes gedunin and its derivatives. The present invention further provides methods for treating disorders wherein Hs?90 inhibition is desired (e.g., proliferative diseases, cancer, inflammatory diseases, fungal infections, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. Celastrol, gedunin, and derivatives thereof are particularly useful in the treatment of prostate cancer, breast cancer, ovarian cancer, lung cancer, and leukemia.
    Type: Application
    Filed: March 30, 2007
    Publication date: October 27, 2011
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Haley Vinson-Hieronymus, Todd R. Golub, Justin Lamb, Kimberly Stegmaier
  • Publication number: 20110263672
    Abstract: Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein.
    Type: Application
    Filed: June 10, 2011
    Publication date: October 27, 2011
    Applicant: Arizona Board of Regents on behalf of the University of Arizona
    Inventor: Garth Powis
  • Publication number: 20110144096
    Abstract: Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C5 or C6 heteroaryl or hetero-cycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods and compounds for the treatment of disorders including neurologic, neuropsychiatric, and metabolic disorders are provided. For example, a method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of the described compounds.
    Type: Application
    Filed: July 28, 2009
    Publication date: June 16, 2011
    Applicant: EMORY UNIVERSITY
    Inventor: Keqiang Ye
  • Publication number: 20100331398
    Abstract: Gossypol and apogossypol derivatives of general formula (1), preparation thereof and use thereof.
    Type: Application
    Filed: December 5, 2008
    Publication date: December 30, 2010
    Applicant: UNIVERSITE DU MAINE (LE MANS)
    Inventors: Jacques Mortier, Anne-Sophie Castanet, Nguyet Trang Thanh Chau
  • Publication number: 20100284925
    Abstract: Methods and compositions for activating PLTP gene expression include administering an effective amount of a limonoid.
    Type: Application
    Filed: October 17, 2007
    Publication date: November 11, 2010
    Inventor: Khew-Voon Chin
  • Publication number: 20100247593
    Abstract: Ectracts and pharmaceuticals form Neobeguea mahafalenstis, the procedures for their preparation, and their use for eliciting sexual enhancing effect and for treatment of sexual dysfuntion, in particular erectile dysfunction and hypoactive desire disorders are disclosed. The structures of the chemical compounds in these extracts causing secual enhancing effect, the preparation of these compounds and the parmaceuticals prepared from them are disclosed.
    Type: Application
    Filed: May 29, 2008
    Publication date: September 30, 2010
    Inventors: Jarl Erik Sylvester Wikberg, Philippe Rasoanaivo, Rasolaondratovo Benoit, Andriantiaray Solofoniaina Razafimahefa
  • Publication number: 20100190985
    Abstract: This invention is related to heteroatom containing diamondoids (i.e., “heterodiamondoids”) which are compounds having a diamondoid nucleus in which one or more of the diamondoid nucleus carbons has been substitutionally replaced with a noncarbon atom. These heteroatom substituents impart desirable properties to the diamondoid. In addition, the heterodiamondoids are functionalized affording compounds carrying one or more functional groups covalently pendant therefrom. This invention is further related to polymerizable functionalized heterodiamondoids. In a preferred aspect of this invention the diamondoid nuclei are triamantane and higher diamondoid nuclei. In another preferred aspect, the heteroatoms are selected to give rise to diamondoid materials which can serve as n- and p-type materials in electronic devices can serve as optically active materials.
    Type: Application
    Filed: December 14, 2009
    Publication date: July 29, 2010
    Applicant: Chevron U.S.A. Inc.
    Inventors: Shenggao Liu, Robert M. Carlson, Jeremy E. Dahl
  • Publication number: 20100130755
    Abstract: There is provided a one-step process for producing a dihydroxy-substituted coumarin dimer compound by a photodimerization reaction of a hydroxy-substituted coumarin compound. The process comprises subjecting a hydroxy-substituted coumarin compound to a photodimerization reaction in a solvent selected from aliphatic ketones having 3 to 10 carbon atoms, aliphatic carboxylic acid esters having 2 to 10 carbon atoms, aliphatic alcohols having 1 to 10 carbon atoms, aliphatic nitriles having 2 to 10 carbon atoms, ethers having 4 to 10 carbon atoms, amides having 3 to 10 carbon atoms, and a mixture thereof to obtain a dihydroxy-substituted coumarin dimer compound.
    Type: Application
    Filed: April 28, 2008
    Publication date: May 27, 2010
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Hideo Suzuki, Takayuki Tamura
  • Publication number: 20100105700
    Abstract: Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.
    Type: Application
    Filed: October 21, 2009
    Publication date: April 29, 2010
    Applicant: LEAD THERAPEUTICS, INC.
    Inventors: Daniel Chu, Peter L. Myers, Bing Wang
  • Publication number: 20100062542
    Abstract: It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By using aflatoxin B2 or its derivative as a hapten compound, an antibody, which shows the same reactivity to individual aflatoxin analogs and is highly tolerant to organic solvents, is obtained. Then, a detection/concentration/purification means and an immunological detection means with the use of the above antibody are constructed. The detection means thus constructed achieves a high sensitivity and excellent quantification properties.
    Type: Application
    Filed: November 13, 2007
    Publication date: March 11, 2010
    Inventors: Mikiko Uchigashima, Shiro Miyake, Hiroshi Yamashita
  • Publication number: 20090018184
    Abstract: Disclosed are compounds that are derivatives of brevetoxin, or PbTx, pharmaceutical formulations comprising the compounds, and methods of regulating mucus transport in a cell, treating mucociliary dysfunction and diseases related to decreased mucus transport, wherein the compounds are of the Formula (I), and Formula (III): wherein R, R1, R2, R3, A, n, and Y are as defined herein for each compound.
    Type: Application
    Filed: July 15, 2008
    Publication date: January 15, 2009
    Inventors: Daniel G. Baden, William M. Abraham, Andrea J. Bourdelais
  • Patent number: 7338720
    Abstract: An organic electroluminescent (EL) device which uses, as a luminescence-assisting agent, a novel coumarin derivative with a specific structure. The coumarin derivative effectively accelerates in such an organic EL device the transfer of excited energy in a host compound to a guest compound. Thus, the coumarin derivative affords the organic EL device which is superior in a color purity, luminescent efficiency and life expectancy when used in combination with appropriate host and guest compounds.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: March 4, 2008
    Assignee: Kabushiki Kaisha Toyota Jidoshokki
    Inventors: Makoto Satsuki, Natsuko Ishida, Sadaharu Suga, Hisayoshi Fujikawa, Yasunori Taga, Satoshi Nakagawa, Takanori Murasaki, Yoshifumi Kato
  • Patent number: 7314942
    Abstract: Alpha-methylenelactone is produced from butyrolactone and valerolactone by the addition of formaldehyde in a supercritical fluid.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: January 1, 2008
    Assignee: E. I. duPont de Nemours & Co.
    Inventors: Keith W. Hutchenson, Leo E. Manzer
  • Patent number: 7252892
    Abstract: An organic electroluminescent (EL) device which contains a novel coumarin derivative composed of a coumarin ring, a naphthalene ring with one or more hydrocarbon groups, and a five-membered hetero ring condensed with the naphthalene ring so as to give an electronic resonance through the coumarin and naphthalene rings. The coumarin derivative emits a visible luminescence with a satisfactory color purity, which consistently continues over a long period of time even at an elevated temperature when used in such an organic device.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: August 7, 2007
    Assignees: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Kabushiki Kaisha Toyota Jidoshokki
    Inventors: Makoto Satsuki, Natsuko Ishida, Sadaharu Suga, Hisayoshi Fujikawa, Yasunori Taga
  • Patent number: 7153946
    Abstract: A molecular conjugate is provided having the formula: wherein R1 is a de-hydroxyl or de-amino moiety respectively of a hydroxyl-bearing or amino-bearing biologically active molecule or an analog or derivative thereof, and Z is —O— or —NH—, respectively, Y is a straight or branched alkyl having 1 to 20 carbons that may be optionally substituted with one or more phenyl, a cycloalkyl optionally substituted with one or more alkyl or phenyl, or an aromatic group optionally substituted with one or more alkyl groups, electron-withdrawing groups, or electron-donating groups; and R2 is —CH?CH(W), —CH(OH)CH(OH)W, or —C(O)H, where W can be H, a straight or branched alkyl having 1 to 20 carbons that may be optionally substituted with one or more phenyl, a cycloalkyl optionally substituted with one or more alkyl or phenyl, or an aromatic group optionally substituted with one or more alkyl groups, electron-withdrawing groups, or electron-donating groups.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: December 26, 2006
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Madhavi C. Chander, Teruna J. Siahaan, Christine R. Xu, Sterling K. Ainsworth
  • Patent number: 7078386
    Abstract: The present invention relates to a medicament, a food, a beverage or a feed, each comprising as an effective ingredient a compound having an enhancing action for NGF production, which is effective for a treatment, an amelioration of symptom, prevention or the like of a disease requiring enhancement of NGF production, wherein the compound has a coumarin and/or chroman backbone. Since no toxicity is especially found in the effective ingredient of the present invention, and there is no risk of incidence of adverse actions, the treatment or the like of the above disease can be safely and appropriately carried out.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: July 18, 2006
    Assignee: Takara Bio, Inc.
    Inventors: Hiromu Ohnogi, Masahiro Shiraga, Hiroaki Sagawa, Ikunoshin Kato
  • Patent number: 6812245
    Abstract: A novel class of antitumour compounds has been recognised based on the isolation from a new marine microbe, strain PO13-046, belonging to the genus Actinomadura sp.), of a compound designated IB-00208. The class of the formulae (I) or (II) where R1 can be hydrogen, acyl, alkyl, alkenyl, aryl, benzyl, alkali metal, and/or sugar, and R2 and R3 can be hydrogen, alkyl, or together R2 and R3 form an unsaturated bond. Such compounds demonstrate an interesting activity several cancel cell lines and against Gram-positive bacteria.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: November 2, 2004
    Assignee: Instituto Biomar S.A.
    Inventors: Librada Maria Cañedo, Dolores Garcia Gravalos, Francisco Romero, Fernando Espliego, Julia Perez-Baz
  • Publication number: 20040077883
    Abstract: A method of isolating terpene trilactones from Ginkgo biloba plant material or extract comprising the steps of suspending the plant material or extract in either water or an aqueous solution of an oxidation reagent; extracting the terpene trilactones using an acceptable extraction agent; separating the organic layer from the aqueous layer; washing the organic layer with an acceptable aqueous salt or hydroxide solution, which may be an alkaline solution; and drying the organic layer to form a dried extract containing terpene trilactones. Further purification by treatment with or filtration over activated charcoal, by treatment with or filtration over alumina and by recrystallization with an acceptable solvent or solvent mixture leads to extracts with a content of terpene trilactones higher than 50%. Unwanted levels of ginkgolic acids are reduced to acceptable levels by reversed phase chromatography.
    Type: Application
    Filed: July 7, 2003
    Publication date: April 22, 2004
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Dirk Lichtblau, Nina Berova, John Berger, Koji Nakanishi
  • Publication number: 20040009928
    Abstract: A novel class of antitumour compounds has been recognised based on the isolation from a new marine microbe, strain PO13-046, belonging to the genus Actinomadura sp.), of a compound designated IB-00208. The class of the formulae (I) or (II) where R1 can be hydrogen, acyl, alkyl, alkenyl, aryl, benzyl, alkali metal, and/or sugar, and R2 and R3 can be hydrogen, alkyl, or together R2 and R3 form an unsaturated bond. Such compounds demonstrate an interesting activity several cancel cell lines and against Gram-positive bacteria.
    Type: Application
    Filed: June 9, 2003
    Publication date: January 15, 2004
    Inventors: Librada Maria Caedo, Dolores Garcia Gravalos, Francisco Romero, Fernando Espliego, Julia Perez-Baz
  • Publication number: 20030158088
    Abstract: The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.
    Type: Application
    Filed: December 17, 2002
    Publication date: August 21, 2003
    Applicant: Advanced Research and Technology Institute, Inc.
    Inventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote
  • Publication number: 20030148210
    Abstract: A polymeric compound for photoresist of the invention includes at least one monomer unit represented by following Formula (I): 1
    Type: Application
    Filed: September 19, 2002
    Publication date: August 7, 2003
    Inventors: Yoshinori Funaki, Kiyoharu Tsutsumi, Keizo Inoue, Tomoko Adachi
  • Publication number: 20030078292
    Abstract: The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: 1
    Type: Application
    Filed: February 6, 2002
    Publication date: April 24, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, Shailaja Kasibhatla, Federico C. Gaeta
  • Publication number: 20020103386
    Abstract: The present invention relates to a process for obtaining Physalis angulata extracts, particularly to isolate ergostane-type steroidal derivatives, such as physalins, which are useful in the treatment of infections caused by protozoans. The physalins of the invention have also prophylactic and therapeutic properties for treating auto-immune diseases in mammals.
    Type: Application
    Filed: October 14, 1999
    Publication date: August 1, 2002
    Inventors: THEREZINHA C. B. TOMASSINI, RICARDO R. DOS SANTOS, MILENA B. P. SOARES, DEISE CRISTINA D. XAVIER, NANCY S. BARBI, IVONE MARIA RIBEIRO, RENATA O. DE A. SOARES, EDMIR FERNANDEZ-FERREIRA
  • Patent number: 6383666
    Abstract: Disclosed are new organometallic complex molecules having light-emitting and electron-transporting characteristics. Also disclosed is organic EL (electroluminescent) devices using these organometallic complex molecules as electron-transporting materials. The organometallic complex molecules are used to form a light-emitting layer with or without doping of another light-emitting material. The organometallic complex molecules can also be used in an electron-transporting layer of the organic EL device. The organic EL devices incorporating the organometallic complex molecules have high thermal stability.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: May 7, 2002
    Assignee: LG Chem, Ltd.
    Inventors: Kongkyeom Kim, Sehwan Son, Okhee Kim, Seok-Hee Yoon, Hyo-Seok Kim, Jaesoon Bae, Youn-Gu Lee
  • Patent number: 6172241
    Abstract: A method for preparing 1,2-dihydroquinolines that is more flexible than the Skraup reaction is provided. The method comprises treating an ortho-alkenyl aniline with a ketone in the presence of a Lewis acid. Novel intermediates and products of this method useful as steroid receptor modulators, as well as pharmaceutical compositions and methods of use thereof are also claimed.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: January 9, 2001
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: James P. Edwards, Todd K. Jones, Josef D. Riggenberg, Erick M. Carreira
  • Patent number: 6149841
    Abstract: Described are novel photochromic benzopyrano-fused naphthopyran compounds, examples of which are naphthopyran compounds having a substituted or unsubstituted benzopyran group fused to one side of the naphtho portion of the naphthopyran and having certain substituents at the position ortho to the oxygen atom of the naphthopyran ring. These compounds may be represented by the following: ##STR1## Also described are polymeric organic host materials that contain or that are coated with such compounds or combinations thereof with complementary photochromic compounds, e.g., certain other naphthopyrans, benzopyrans, and spiro(indoline)type compounds.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: November 21, 2000
    Assignee: PPG Industries Ohio, Inc.
    Inventor: Anil Kumar
  • Patent number: 5985913
    Abstract: The present invention provides a compound in substantially pure form having the structure: ##STR1## wherein each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 may independently be hydrogen, halogen, nitro, CF.sub.3, hydroxy, C.sub.1-5 alkyl, aryl or OR.sub.9, wherein R.sub.9 is C.sub.1-5 alkyl, wherein R.sub.10 is COC.sub.1-5 alkyl; or wherein any two consecutive R groups may be members of a C.sub.5 -C.sub.6 membered ring, and wherein the intracyclic-dashed line represents a covalent bond which may be present or absent, with the proviso that when R.sub.10 is present, the exocyclic-covalent bond is absent, and when R.sub.10 is absent, the exocyclic-covalent bond is present, and with the proviso that when R.sub.10 is absent, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 cannot all be hydrogen and when R.sub.10 is absent, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 cannot all be hydrogen when either R.sub.1, R.sub.2, R.sub.3, or R.sub.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: November 16, 1999
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Jonathan Gareth Williams, David R. Houck, David Edward Smith, Daniel Lee Rathbone, David Charles Billington, Bernard T. Golding, Eric W. Collington, John Kitchin, Nicholas Rich
  • Patent number: 5965493
    Abstract: The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.
    Type: Grant
    Filed: May 1, 1997
    Date of Patent: October 12, 1999
    Assignees: Advanced Research and Technology Institute, Inc., The Board of Governors of Wayne State University, Purdue Reseach Foundation
    Inventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote
  • Patent number: 5849748
    Abstract: The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: December 15, 1998
    Assignee: Advanced Research and Technology Institute, Inc.
    Inventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote
  • Patent number: 5652096
    Abstract: Hybridization method for discriminating between complementarity and partial complementarity of DNA base sequences. Kinetic covalent entrapment of PCR-amplified target DNA is achieved through the use of crosslinkable probes. A crosslinking site is introduced into the target DNA via the PCR amplification process. Problems with renaturation of target DNA in the PCR process and in the hybridization reaction are minimized.
    Type: Grant
    Filed: April 20, 1994
    Date of Patent: July 29, 1997
    Assignee: HRI Research Inc.
    Inventor: George D. Cimino
  • Patent number: 5639712
    Abstract: Quassinoid compounds, compositions, and methods of using them for treating cells and solid tumors, and inhibiting plant growth.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: June 17, 1997
    Assignees: Indiana University Foundation, Purdue Research Foundation, Bd. of Governors of Wayne State Univ.
    Inventors: Paul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote